摘要
目的:观察Pixel 2 940 nm点阵激光联合他克莫司软膏治疗肢端型白癜风的临床效果。方法:选取梅州市第二中医医院2019年5月-2021年5月收治的肢端型白癜风患者62例为研究对象,按照随机数字表法将其分为治疗组和对照组,各31例。对照组予以他克莫司软膏治疗,治疗组予以Pixel 2 940 nm点阵激光联合他克莫司软膏治疗。两组均以12周为1个疗程,共治疗2个疗程。对比两组临床疗效、不良反应发生率和复发率。结果:治疗12、24周后,治疗组总有效率(45.16%、70.97%)均明显高于对照组(19.35%、41.94%)(P<0.05);治疗期间对照组不良反应发生率为12.90%,明显低于治疗组的41.94%(P<0.05);治疗组复发率为4.55%(1/22),低于对照组的61.54%(8/13)(P<0.05)。结论:Pixel 2 940 nm点阵激光联合他克莫司软膏治疗肢端型白癜风虽会增加不良反应,但见效快,临床疗效好,能够显著降低复发率,值得在临床上推广应用。
Objective: To observe the clinical effect of Pixel 2 940 nm fractional laser combined with Tacrolimus Ointment in the treatment of acrofacial vitiligo. Method: A total of 62 patients with acrofacial vitiligo who were admitted to Meizhou Second Chinese Medicine Hospital from May 2019 to May 2021 were selected as the research subjects and divided into the treatment group and the control group according to the random number table,with 31 cases in each group. The control group was treated with Tacrolimus Ointment, and the treatment group was treated with Pixel 2 940 nm fractional laser combined with Tacrolimus Ointment. Two groups were treated for two courses with 12 weeks as a course of treatment. Clinical efficacy, incidence of adverse reactions and recurrence rate were compared between the two groups. Result: After 12 and 24 weeks of treatment, the total effective rates of the treatment group(45.16%, 70.97%) were significantly higher than those of the control group(19.35%, 41.94%)(P<0.05). During the treatment, the incidence of adverse reactions in the control group was 12.90%, which was significantly lower than 41.94% in the treatment group(P<0.05). The recurrence rate of the treatment group was 4.55%(1/22), which was lower than 61.54%(8/13) of the control group(P<0.05). Conclusion: Pixel 2 940 nm fractional laser combined with Tacrolimus Ointment in the treatment of acrofacial vitiligo may increase the adverse reactions, bu it has a rapid effect and good clinical efficacy, and can significantly reduce the recurrence rate, which is worthy of clinical application.
作者
曾宝英
罗智华
温秋娥
吴训莹
古宇环
ZENG Baoying;LUO Zhihua;WEN Qiue;WU Xunying;GU Yuhuan(Meizhou Second Chinese Medicine Hospital,Guangdong Province,Meizhou 514011,China;不详)
出处
《中国医学创新》
CAS
2023年第2期136-139,共4页
Medical Innovation of China
基金
梅州市科技计划项目(2021B116)。
